Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

Trial Profile

A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asunercept (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors CANbridge Life Sciences; CANbridge Pharmaceuticals
  • Most Recent Events

    • 28 Mar 2023 According to a CANbridge Pharmaceuticals media release, data from this trial were presented at the ESMO Sarcoma and Rare Cancers Annual Meeting
    • 17 Mar 2023 Long-term follow up data results published in the CANbridge Pharmaceuticals Media Release.
    • 13 Mar 2023 According to a CANbridge Pharmaceuticals media release, an abstract on the long-term follow up data from the CAN008 Phase 1/2 trial in glioblastoma multiforme has been accepted for a poster presentation by the European Society for Medical Oncology (ESMO) Sarcoma and Rare Cancers Annual Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top